Speaker
Prof.
Alfred Morgenstern
(European Commission, Joint Research Centre (JRC), Karlsruhe, Germany)
Description
225Ac-PSMA617 is a novel and highly promising compound for treatment of prostate cancer. Since treatment of the first patient in early 2014, to date more than 330 prostate cancer patients have received a total of approximately 800 therapeutic applications through collaboration of the European Commission's Joint Research Center with hospitals in Heidelberg (Germany), Pretoria (South Africa), Munich (Germany) and Warsaw (Poland). This lecture will give an overview on the current state of clinical development of 225Ac-PSMA617, focusing on its benefits and limitations for treatment of patients suffering from late-stage prostate cancer that have exhausted available established therapies, for patients that have also failed therapy with 177Lu-PSMA617 and for patients that have received fewer pre-treatments, e.g. chemo-naive patients. The safety and efficacy of various dosing regimes, e.g. administration of fixed activities, dose de-escalation strategies and combination therapies with 177Lu-PSMA617 as well as strategies for mitigation of xerostomia, the main toxicity associated with 225Ac-PSMA617 therapy will be reviewed.
| Email Address | alfred.morgenstern@ec.europa.e |
|---|---|
| Presentation Type | Contributed Oral |
Primary author
Prof.
Alfred Morgenstern
(European Commission, Joint Research Centre (JRC), Karlsruhe, Germany)
